Hoth Therapeutics Inc (HOTH)

NASDAQ
0.3400
+0.0016(+0.47%)
After Hours
0.3500
+0.0100(+2.9412%)
- Real-time Data
  • Volume:
    43,312
  • Day's Range:
    0.3400 - 0.3489
  • 52 wk Range:
    0.3200 - 1.7500

HOTH Overview

Prev. Close
0.3384
Day's Range
0.34-0.3489
Revenue
-
Open
0.3489
52 wk Range
0.32-1.75
EPS
-0.467
Volume
43,312
Market Cap
10.95M
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
581,177
P/E Ratio
-0.824
Beta
0.912
1-Year Change
-70.83%
Shares Outstanding
32,211,128
Next Earnings Date
Nov 30, 2022
What is your sentiment on Hoth Therapeutics?
or
Market is currently closed. Voting is open during market hours.

Hoth Therapeutics Inc News

Welcome to Your News Upgrade

Be the First to Know and Act on Market Moving News.

Welcome to Your News Upgrade

Hoth Therapeutics Inc Analysis

Hoth Therapeutics Inc Company Profile

Hoth Therapeutics Inc Company Profile

Employees
5

Hoth Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for unmet medical needs. It is involved in the development of HT-001, a topical formulation for the treatment of patients with rash and skin disorders associated with initial and repeat courses of tyrosine kinase epidermal growth factor receptor inhibitor therapy; HT-KIT to treat mast-cell derived cancers and anaphylaxis; HT-ALZ for the treatment and/or prevention of Alzheimer’s or other neuroinflammatory diseases; HT-003 to treat inflammatory bowel diseases, as well as acne and psoriasis; HT-004 for treatment of asthma and allergies using inhalational administration; HT-006 to treat lung diseases resulting from bacterial infections; and HT-002, a novel peptide for treating COVID-19. The company is also developing BioLexa Platform, a proprietary, patented, drug compound platform which is in phase I clinical trial for the treatment of eczema; and HT-005 for treating patients with lupus. The company has license agreements with the George Washington University; the University of Maryland; Isoprene Pharmaceuticals, Inc.; the North Carolina State University; Chelexa BioSciences, Inc.; Zylö Therapeutics, Inc., and the University of Cincinnati. It also has a research collaboration agreement with Weill Cornell Medicine to develop HT-003. Hoth Therapeutics, Inc. was incorporated in 2017 and is headquartered in New York, New York.

Read More

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong SellStrong SellStrong SellStrong SellStrong Sell
Technical IndicatorsSellBuyBuyStrong SellStrong Sell
SummaryStrong SellNeutralNeutralStrong SellStrong Sell
  • Reverse Stock Split
    0
    • lets gooooo closed by 1.60
      0
      • Penso che questi delinquenti abbiano dato l'ultimo colpetto in basso per fare uscire i piccolini, prima di farla salire a 3 dollari...io ho continuato a comprare, prepararsi a rialzo stellare
        1
        • pensi che questo andrà a 3?
          0
      • could this make a push for 1?
        0
        • I took a big position here , at a price of $0.58 , I hope there will be a squeeze short here soon
          0
          • Apparently good news about treatment of Alzheimers
            0
            • Wow! Any relevant news?
              0
              • 🚀🚀🚀
                0
                • Buy, TP 5-6
                  1
                  • Jan 28, 2021, 08:02 ET Therapeutics Expands Research Collaboration Agreement with Weill Cornell Medicine to Continue the Advancement of HT-003 for Acne Treatment Research The extended research agreement builds on the positive results generated for HT-003 as an acne therapeutic
                    1
                    • u're also here?
                      0